Market revenue in 2023 | USD 27.8 million |
Market revenue in 2030 | USD 51.6 million |
Growth rate | 9.2% (CAGR from 2023 to 2030) |
Largest segment | Human donor tissue-derived products |
Fastest growing segment | Human Donor Tissue-Derived Products |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Human Donor Tissue-Derived Products, Acellular Animal-derived Products |
Key market players worldwide | 3M Co, Organogenesis Holdings Inc Class A, Integra Lifesciences Holdings Corp, Smith & Nephew PLC, MiMedx Group Inc, Essity AB Class B, Stryker Corp, Vericel Corp, Mallinckrodt PLC Ordinary Shares - New, Tissue Regenix |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biological skin substitutes market will help companies and investors design strategic landscapes.
Human donor tissue-derived products was the largest segment with a revenue share of 67.63% in 2023. Horizon Databook has segmented the China biological skin substitutes market based on human donor tissue-derived products, acellular animal-derived products covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the most technologically advanced countries, which significantly contributes to the healthcare industry of the region. In addition, rise in the geriatric population and presence of a large fraction of the population belonging to the middle-income group increases the demand for innovative & cost-effective medical equipment, which is expected to attract major medical device companies to this region.
The low cost of labor is one of the key factors, and outsourcing clinical research services in China is cost-effective. Owing to this reason, the number of clinical research studies in China is expected to increase. This is expected to boost competition in the market in China.
For instance, in March 2023, GE Healthcare established a long-term joint venture with Sinopharm as part of its strategy to further penetrate the medical device market in China. China held the second-largest share of the overall medical device outsourcing market owing to the increase in the number of collaborations of industry players with Original Equipment Manufacturers (OEMs) present in this region.
Horizon Databook provides a detailed overview of country-level data and insights on the China biological skin substitutes market , including forecasts for subscribers. This country databook contains high-level insights into China biological skin substitutes market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account